{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T11:22:56Z","timestamp":1778757776108,"version":"3.51.4"},"reference-count":91,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1016\/j.beha.2011.03.004","type":"journal-article","created":{"date-parts":[[2011,5,10]],"date-time":"2011-05-10T07:14:07Z","timestamp":1305011647000},"page":"217-229","source":"Crossref","is-referenced-by-count":17,"title":["Molecular engineering to improve antibodies\u2019 anti-lymphoma activity"],"prefix":"10.1016","volume":"24","author":[{"given":"Matthias","family":"Peipp","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan G.J.","family":"van de Winkel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Valerius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2011.03.004_bib1","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/256495a0","article-title":"Continuous cultures of fused cells secreting antibody of predefined specificity","volume":"256","author":"K\u00f6hler","year":"1975","journal-title":"Nature"},{"key":"10.1016\/j.beha.2011.03.004_bib2","first-page":"1","article-title":"Immunologic classification of leukemia and lymphoma","volume":"68","author":"Foon","year":"1986","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.03.004_bib3","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1182\/blood.V69.2.584.584","article-title":"Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B-cell lymphomas","volume":"694","author":"Press","year":"1987","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.03.004_bib4","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1098\/rspl.1899.0121","article-title":"On immunity with special reference to cell life","volume":"66","author":"Ehrlich","year":"1900","journal-title":"Proc Royal Soc London"},{"issue":"6008","key":"10.1016\/j.beha.2011.03.004_bib5","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/314268a0","article-title":"A hapten-specific chimaeric IgE antibody with human physiological effector function","volume":"314","author":"Neuberger","year":"1985","journal-title":"Nature"},{"key":"10.1016\/j.beha.2011.03.004_bib6","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/332323a0","article-title":"Reshaping human antibodies for therapy","volume":"332","author":"Riechmann","year":"1988","journal-title":"Nature"},{"key":"10.1016\/j.beha.2011.03.004_bib7","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1146\/annurev.immunol.18.1.739","article-title":"Multiple roles for the major histocompatibility complex class I- related receptor FcRn","volume":"18","author":"Ghetie","year":"2000","journal-title":"Annu Rev Immunol"},{"issue":"6","key":"10.1016\/j.beha.2011.03.004_bib8","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin\u2019s lymphoma","volume":"90","author":"Maloney","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.03.004_bib9","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1056\/NEJMra0708875","article-title":"Monoclonal antibody therapy for B- cell non-Hodgkin\u2019s lymphoma","volume":"359","author":"Cheson","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2011.03.004_bib10","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nri1837","article-title":"Potent antibody therapeutics by design","volume":"6","author":"Carter","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.beha.2011.03.004_bib11","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1056\/NEJM198203043060906","article-title":"Treatment of B-cell lymphoma with monoclonal ant-idiotype antibody","volume":"306","author":"Miller","year":"1982","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.beha.2011.03.004_bib12","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.blre.2008.09.001","article-title":"Vaccines for lymphomas: idiotype vaccines and beyond","volume":"23","author":"Houot","year":"2009","journal-title":"Blood Rev"},{"key":"10.1016\/j.beha.2011.03.004_bib13","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1159\/000082102","article-title":"The biology of CD20 and its potential as a target for mAb therapy","volume":"8","author":"Cragg","year":"2005","journal-title":"Curr Dir Autoimmun"},{"issue":"16","key":"10.1016\/j.beha.2011.03.004_bib14","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1016\/j.molimm.2007.06.151","article-title":"Mechanisms of killing by anti-CD20 monoclonal antibodies","volume":"44","author":"Glennie","year":"2007","journal-title":"Mol Immunol"},{"key":"10.1016\/j.beha.2011.03.004_bib15","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","article-title":"Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity","volume":"115","author":"M\u00f6ssner","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.03.004_bib16","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/j.jmb.2006.01.023","article-title":"Antibody elbow angles are influenced by their light chain class","volume":"357","author":"Stanfield","year":"2006","journal-title":"J Mol Biol"},{"issue":"3","key":"10.1016\/j.beha.2011.03.004_bib17","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1182\/blood.V99.3.1038","article-title":"The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction","volume":"99","author":"Byrd","year":"2002","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2011.03.004_bib18","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.4049\/jimmunol.171.3.1581","article-title":"Complement activation determines the therapeutic activity of rituximab in vivo","volume":"171","author":"Di Gaetano","year":"2003","journal-title":"J\u00a0Immunol"},{"issue":"5753","key":"10.1016\/j.beha.2011.03.004_bib19","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1126\/science.1118948","article-title":"Divergent immunoglobulin g subclass activity through selective Fc receptor binding","volume":"310","author":"Nimmerjahn","year":"2005","journal-title":"Science (New York, N.Y)"},{"issue":"4","key":"10.1016\/j.beha.2011.03.004_bib20","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/74704","article-title":"Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets","volume":"6","author":"Clynes","year":"2000","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.beha.2011.03.004_bib21","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1084\/jem.20040119","article-title":"The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy","volume":"199","author":"Uchida","year":"2004","journal-title":"J Exp Med"},{"issue":"2","key":"10.1016\/j.beha.2011.03.004_bib22","doi-asserted-by":"crossref","first-page":"817","DOI":"10.4049\/jimmunol.174.2.817","article-title":"Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy","volume":"174","author":"Gong","year":"2005","journal-title":"J\u00a0Immunol"},{"issue":"8","key":"10.1016\/j.beha.2011.03.004_bib23","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1158\/0008-5472.CAN-09-4109","article-title":"In vivo cytotoxicity of Type I CD20 antibodies critically depends on Fc receptor ITAM signaling","volume":"70","author":"de Haij","year":"2010","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.beha.2011.03.004_bib24","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1182\/blood.V99.3.754","article-title":"Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene","volume":"99","author":"Cartron","year":"2002","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.beha.2011.03.004_bib25","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1200\/JCO.2003.05.013","article-title":"Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma","volume":"21","author":"Weng","year":"2003","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.beha.2011.03.004_bib26","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nrd2241","article-title":"Development trends for monoclonal antibody cancer therapeutics","volume":"6","author":"Reichert","year":"2007","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"10.1016\/j.beha.2011.03.004_bib27","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0161-5890(85)90151-8","article-title":"Immunoglobulin G: functional sites","volume":"22","author":"Burton","year":"1985","journal-title":"Mol Immunol"},{"key":"10.1016\/j.beha.2011.03.004_bib28","first-page":"1","article-title":"Metabolism of immunoglobulins","volume":"13","author":"Waldmann","year":"1969","journal-title":"Prog Allergy"},{"issue":"16","key":"10.1016\/j.beha.2011.03.004_bib29","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1182\/blood-2008-09-179754","article-title":"Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses","volume":"113","author":"Bruhns","year":"2009","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.beha.2011.03.004_bib30","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.1182\/blood-2002-03-0687","article-title":"Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing","volume":"100","author":"Dechant","year":"2002","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.beha.2011.03.004_bib31","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0167-5699(93)90166-I","article-title":"Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications","volume":"14","author":"van de Winkel","year":"1993","journal-title":"Immunol Today"},{"issue":"3","key":"10.1016\/j.beha.2011.03.004_bib32","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1182\/blood.V90.3.1109","article-title":"Fc gammaRIIIa-158V\/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L\/R\/H phenotype","volume":"90","author":"Koene","year":"1997","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2011.03.004_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2249.1991.tb08115.x","article-title":"The effect of antibody isotype and antigenic epitope density on the complement-fixing activity of immune complexes: a systematic study using chimaeric anti-NIP antibodies with human Fc regions","volume":"84","author":"Lucisano Valim","year":"1991","journal-title":"Clin Exp Immunol"},{"issue":"3","key":"10.1016\/j.beha.2011.03.004_bib34","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/PPO.0b013e318172d704","article-title":"Antibody-drug conjugates for cancer therapy","volume":"14","author":"Carter","year":"2008","journal-title":"Cancer J"},{"issue":"6","key":"10.1016\/j.beha.2011.03.004_bib35","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/MOH.0b013e3282efb17c","article-title":"Radioimmunotherapy for treatment of B-cell lymphomas and other hematologic malignancies","volume":"14","author":"Park","year":"2007","journal-title":"Curr Opin Hematol"},{"issue":"9","key":"10.1016\/j.beha.2011.03.004_bib36","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1038\/nbt1135","article-title":"Human antibodies from transgenic animals","volume":"23","author":"Lonberg","year":"2005","journal-title":"Nat Biotechnol"},{"issue":"5939","key":"10.1016\/j.beha.2011.03.004_bib37","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1126\/science.1172447","article-title":"Knockout rats via embryo microinjection of zinc-finger nucleases","volume":"325","author":"Geurts","year":"2009","journal-title":"Science"},{"issue":"6336","key":"10.1016\/j.beha.2011.03.004_bib38","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/352624a0","article-title":"Making antibody fragments using phage display libraries","volume":"352","author":"Clackson","year":"1991","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.beha.2011.03.004_bib39","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.copbio.2007.10.011","article-title":"Human monoclonal antibodies by immortalization of memory B cells","volume":"18","author":"Lanzavecchia","year":"2007","journal-title":"Curr Opin Biotechnol"},{"issue":"5","key":"10.1016\/j.beha.2011.03.004_bib40","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/j.jmb.2009.12.046","article-title":"Engineering fully human monoclonal antibodies from murine variable regions","volume":"396","author":"Bernett","year":"2010","journal-title":"J Mol Biol"},{"issue":"6069","key":"10.1016\/j.beha.2011.03.004_bib41","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/321522a0","article-title":"Replacing the complementarity-determining regions in a human antibody with those from a mouse","volume":"321","author":"Jones","year":"1986","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.beha.2011.03.004_bib42","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.4049\/jimmunol.179.5.2815","article-title":"Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigen","volume":"179","author":"Tang","year":"2007","journal-title":"J Immunol"},{"issue":"24","key":"10.1016\/j.beha.2011.03.004_bib43","doi-asserted-by":"crossref","first-page":"5007","DOI":"10.1182\/blood-2009-06-225474","article-title":"Characterization of a rituximab variant with potent antitumor activity against rituximab-resistant B-cell lymphoma","volume":"114","author":"Li","year":"2009","journal-title":"Blood"},{"issue":"1-2","key":"10.1016\/j.beha.2011.03.004_bib44","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0165-2478(02)00019-6","article-title":"Interaction sites on human IgG-Fc for FcgammaR: current models","volume":"82","author":"Jefferis","year":"2002","journal-title":"Immunol Lett"},{"issue":"6793","key":"10.1016\/j.beha.2011.03.004_bib45","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/35018508","article-title":"The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex","volume":"406","author":"Sondermann","year":"2000","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.beha.2011.03.004_bib46","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0167-7799(96)10062-7","article-title":"Effect of glycosylation on antibody function: implications for genetic engineering","volume":"15","author":"Wright","year":"1997","journal-title":"Trends Biotechnol"},{"issue":"3","key":"10.1016\/j.beha.2011.03.004_bib47","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nrd2804","article-title":"Glycosylation as a strategy to improve antibody-based therapeutics","volume":"8","author":"Jefferis","year":"2009","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"10.1016\/j.beha.2011.03.004_bib48","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1074\/jbc.M210665200","article-title":"The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity","volume":"278","author":"Shinkawa","year":"2003","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.beha.2011.03.004_bib49","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/bit.22535","article-title":"Rapid production of recombinant human IgG With improved ADCC effector function in a transient expression system","volume":"105","author":"van Berkel","year":"2010","journal-title":"Biotechnol Bioeng"},{"issue":"2","key":"10.1016\/j.beha.2011.03.004_bib50","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/6179","article-title":"Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity","volume":"17","author":"Umana","year":"1999","journal-title":"Nat Biotechnol"},{"issue":"4","key":"10.1016\/j.beha.2011.03.004_bib51","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/bit.1119","article-title":"Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC gamma RIII","volume":"74","author":"Davies","year":"2001","journal-title":"Biotechnol Bioeng"},{"issue":"5","key":"10.1016\/j.beha.2011.03.004_bib52","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/bit.20151","article-title":"Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity","volume":"87","author":"Yamane-Ohnuki","year":"2004","journal-title":"Biotechnol Bioeng"},{"issue":"30","key":"10.1016\/j.beha.2011.03.004_bib53","doi-asserted-by":"crossref","first-page":"26733","DOI":"10.1074\/jbc.M202069200","article-title":"Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity","volume":"277","author":"Shields","year":"2002","journal-title":"J Biol Chem"},{"issue":"8","key":"10.1016\/j.beha.2011.03.004_bib54","doi-asserted-by":"crossref","first-page":"5032","DOI":"10.1074\/jbc.M510171200","article-title":"The carbohydrate at Fcgamma RIIIa ASN162: an element required for high affinity binding to non-fucosylated lgG glycoforms","volume":"281","author":"Ferrara","year":"2005","journal-title":"J Biol Chem"},{"issue":"18 Pt 1","key":"10.1016\/j.beha.2011.03.004_bib55","doi-asserted-by":"crossref","first-page":"6248","DOI":"10.1158\/1078-0432.CCR-04-0850","article-title":"Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcgammaRIIIa functional polymorphism","volume":"10","author":"Niwa","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.beha.2011.03.004_bib56","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.exphem.2008.11.006","article-title":"Nonfucosylated rituximab potentiates human neutrophil phagocytosis through its high binding for FcgammaRIIIb and MHC class II expression on the phagocytotic neutrophils","volume":"37","author":"Shibata-Koyama","year":"2009","journal-title":"Exp Hematol"},{"issue":"6","key":"10.1016\/j.beha.2011.03.004_bib57","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1182\/blood-2008-03-144600","article-title":"Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells","volume":"112","author":"Peipp","year":"2008","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2011.03.004_bib58","doi-asserted-by":"crossref","first-page":"6591","DOI":"10.1074\/jbc.M009483200","article-title":"High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R","volume":"276","author":"Shields","year":"2001","journal-title":"J Biol Chem"},{"issue":"11","key":"10.1016\/j.beha.2011.03.004_bib59","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1073\/pnas.0508123103","article-title":"Engineered antibody Fc variants with enhanced effector function","volume":"103","author":"Lazar","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"18","key":"10.1016\/j.beha.2011.03.004_bib60","doi-asserted-by":"crossref","first-page":"8882","DOI":"10.1158\/0008-5472.CAN-07-0696","article-title":"Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors","volume":"67","author":"Stavenhagen","year":"2007","journal-title":"Cancer Res"},{"issue":"19","key":"10.1016\/j.beha.2011.03.004_bib61","doi-asserted-by":"crossref","first-page":"8049","DOI":"10.1158\/0008-5472.CAN-08-2268","article-title":"Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia","volume":"68","author":"Horton","year":"2008","journal-title":"Cancer Res"},{"issue":"16","key":"10.1016\/j.beha.2011.03.004_bib62","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1182\/blood-2008-10-182048","article-title":"The impact of Fc engineering on an anti-CD19 antibody: increased Fcgamma receptor affinity enhances B-cell clearing in nonhuman primates","volume":"113","author":"Zalevsky","year":"2009","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.beha.2011.03.004_bib63","doi-asserted-by":"crossref","first-page":"5322","DOI":"10.1182\/blood-2009-01-200469","article-title":"Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model","volume":"114","author":"Wang","year":"2009","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2011.03.004_bib64","doi-asserted-by":"crossref","first-page":"4178","DOI":"10.4049\/jimmunol.164.8.4178","article-title":"Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc","volume":"164","author":"Idusogie","year":"2000","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.beha.2011.03.004_bib65","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.4049\/jimmunol.166.4.2571","article-title":"Engineered antibodies with increased activity to recruit complement","volume":"166","author":"Idusogie","year":"2001","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.beha.2011.03.004_bib66","doi-asserted-by":"crossref","DOI":"10.4161\/mabs.2.2.11158","article-title":"Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions","volume":"2","author":"Moore","year":"2010","journal-title":"MAbs"},{"issue":"9","key":"10.1016\/j.beha.2011.03.004_bib67","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1023\/A:1008416911099","article-title":"Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin\u2019s lymphoma","volume":"9","author":"Berinstein","year":"1998","journal-title":"Ann Oncol"},{"issue":"15","key":"10.1016\/j.beha.2011.03.004_bib68","doi-asserted-by":"crossref","first-page":"7630","DOI":"10.1158\/0008-5472.CAN-05-4010","article-title":"The impact of target dynamics on the dose-effect relationship of a therapeutic antibody against epidermal growth factor receptor","volume":"66","author":"Lammerts van Bueren","year":"2006","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.beha.2011.03.004_bib69","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/ijc.2910560413","article-title":"Internalization and intracellular processing of an anti-B-cell lymphoma monoclonal antibody, LL2","volume":"56","author":"Shih","year":"1994","journal-title":"Int J Cancer"},{"issue":"6504","key":"10.1016\/j.beha.2011.03.004_bib70","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/372379a0","article-title":"Crystal structure of the complex of rat neonatal Fc receptor with Fc","volume":"372","author":"Burmeister","year":"1994","journal-title":"Nature"},{"issue":"8-9","key":"10.1016\/j.beha.2011.03.004_bib71","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/j.molimm.2009.01.026","article-title":"Structural characterization of a human Fc fragment engineered for extended serum half-life","volume":"46","author":"Oganesyan","year":"2009","journal-title":"Mol Immunol"},{"issue":"2","key":"10.1016\/j.beha.2011.03.004_bib72","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/nbt.1601","article-title":"Enhanced antibody half-life improves in vivo activity","volume":"28","author":"Zalevsky","year":"2010","journal-title":"Nat Biotechnol"},{"issue":"1\u20132","key":"10.1016\/j.beha.2011.03.004_bib73","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jim.2009.10.009","article-title":"High throughput screening for antibody induced complement-dependent cytotoxicity in early antibody discovery using homogeneous macroconfocal fluorescence imaging","volume":"352","author":"Gerritsen","year":"2010","journal-title":"J Immunol Methods"},{"issue":"6","key":"10.1016\/j.beha.2011.03.004_bib74","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1182\/blood-2004-01-0039","article-title":"Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas","volume":"104","author":"Teeling","year":"2004","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2011.03.004_bib75","doi-asserted-by":"crossref","first-page":"4338","DOI":"10.4049\/jimmunol.180.6.4338","article-title":"Tumor cell killing mechanisms of epidermal growth factor receptor (EGFR) antibodies are not affected by lung cancer-associated EGFR kinase mutations","volume":"180","author":"Peipp","year":"2008","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.beha.2011.03.004_bib76","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.immuni.2005.11.010","article-title":"Fcgamma receptors: old friends and new family members","volume":"24","author":"Nimmerjahn","year":"2006","journal-title":"Immunity"},{"issue":"5","key":"10.1016\/j.beha.2011.03.004_bib77","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.immuni.2008.04.003","article-title":"CD28 superagonists: what makes the difference in humans?","volume":"28","author":"Schraven","year":"2008","journal-title":"Immunity"},{"issue":"5","key":"10.1016\/j.beha.2011.03.004_bib78","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1200\/JCO.2009.22.8254","article-title":"Investigational immunotherapeutics for B-cell malignancies","volume":"28","author":"Quintas-Cardama","year":"2010","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.beha.2011.03.004_bib79","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/j.1365-2141.2007.06974.x","article-title":"Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcgammaRIIIA\/CD16","volume":"140","author":"de Romeuf","year":"2008","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.beha.2011.03.004_bib80","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.coi.2008.06.012","article-title":"Molecular engineering and design of therapeutic antibodies","volume":"20","author":"Presta","year":"2008","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.beha.2011.03.004_bib81","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1159\/000319350","article-title":"IgG effector mechanisms","volume":"65","author":"Clark","year":"1997","journal-title":"Chem Immunol"},{"issue":"8","key":"10.1016\/j.beha.2011.03.004_bib82","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1182\/blood-2006-04-020057","article-title":"Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab","volume":"108","author":"Bowles","year":"2006","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2011.03.004_bib83","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1158\/0008-5472.CAN-07-6297","article-title":"Engineered antibodies of IgG1\/IgG3 mixed isotype with enhanced cytotoxic activities","volume":"68","author":"Natsume","year":"2008","journal-title":"Cancer Res"},{"issue":"33","key":"10.1016\/j.beha.2011.03.004_bib84","doi-asserted-by":"crossref","first-page":"23514","DOI":"10.1074\/jbc.M604292200","article-title":"Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn)","volume":"281","author":"Dall\u2019Acqua","year":"2006","journal-title":"J Biol Chem"},{"issue":"9","key":"10.1016\/j.beha.2011.03.004_bib85","doi-asserted-by":"crossref","first-page":"5171","DOI":"10.4049\/jimmunol.169.9.5171","article-title":"Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences","volume":"169","author":"Dall\u2019Acqua","year":"2002","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.beha.2011.03.004_bib86","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1124\/dmd.106.011734","article-title":"Humanized IgG1 variants with differential binding properties to the neonatal Fc receptor: relationship to pharmacokinetics in mice and primates","volume":"35","author":"Datta-Mannan","year":"2007","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1016\/j.beha.2011.03.004_bib87","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1074\/jbc.M607161200","article-title":"Monoclonal antibody clearance. Impact of modulating the interaction of IgG with the neonatal Fc receptor","volume":"282","author":"Datta-Mannan","year":"2007","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.beha.2011.03.004_bib88","doi-asserted-by":"crossref","first-page":"346","DOI":"10.4049\/jimmunol.176.1.346","article-title":"An engineered human IgG1 antibody with longer serum half-life","volume":"176","author":"Hinton","year":"2006","journal-title":"J Immunol"},{"issue":"12","key":"10.1016\/j.beha.2011.03.004_bib89","doi-asserted-by":"crossref","first-page":"7663","DOI":"10.4049\/jimmunol.0804182","article-title":"Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates","volume":"182","author":"Yeung","year":"2009","journal-title":"J Immunol"},{"issue":"8","key":"10.1016\/j.beha.2011.03.004_bib90","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1158\/0008-5472.CAN-09-4580","article-title":"A therapeutic anti-VEGF antibody with increased potency independent of pharmacokinetic half-life","volume":"70","author":"Yeung","year":"2010","journal-title":"Cancer Res"},{"issue":"12","key":"10.1016\/j.beha.2011.03.004_bib91","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1093\/intimm\/dxl110","article-title":"Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease","volume":"18","author":"Petkova","year":"2006","journal-title":"Int Immunol"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692611000314?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692611000314?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T01:31:52Z","timestamp":1592530312000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692611000314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":91,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["S1521692611000314"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2011.03.004","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2011,6]]}}}